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Prognostic value of neutrophil/
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patients
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Several studies have reported that the neutrophil to lymphocyte ratio (NLR) and mean platelet 
volume (MPV) are associated with poor prognosis. This study investigated whether NLR and/or 
the MPV/platelet ratio could function as predictive markers of mortality in critically ill patients. We 
retrospectively reviewed 1,154 patients admitted to the intensive care unit (ICU) between January 
2017 and December 2017. Patients were divided into 2 groups according to 1‑year mortality. We 
compared the NLR and MPV/platelet ratio on each day of ICU admission. Patients were classified 
into tertiles based on their NLR and MPV/platelet ratios, and the incidence of 1‑year mortality was 
compared. Kaplan–Meier survival curves were plotted to evaluate their potential as prognostic factors 
for 1‑year mortality. The NLR and MPV/platelet ratio were higher in the non‑survivor group than 
in the survivor group. The incidence of 1‑year mortality was the highest in the third tertile for both 
the NLR and MPV/platelet ratio. The MPV/platelet ratio was an independent predictor for 1‑year 
mortality based on the Kaplan–Meier survival analysis. Our data showed that the MPV/platelet ratio is 
a predictive factor for 1‑year mortality in critically ill patients.
The ability to predict a poor prognosis in critically ill patients is vitally important in determining a treatment 
strategy. Although several predictive tools have been suggested to predict mortality in critically ill patients, 
including the Acute Physiological and Chronic Health Evaluation (APACHE) II and the Sequential Organ Fail-
ure Assessment (SOFA), there are few predictive factors that are accurate, easy to use, and readily available in 
critically ill patients with various  diseases1,2.
Most critically ill patients have cardiovascular instability and systemic inflammatory responses. For this 
reason, there has been extensive investigation into the prognostic abilities of various inflammatory biomarkers, 
including C-reactive protein (CRP) and procalcitonin, in critically ill  patients3,4. However, there is an emerging 
need for a simple and readily available inflammatory marker such as the neutrophil to lymphocyte ratio (NLR) 
or mean platelet volume (MPV) to function as a prognostic indicator for patients in the intensive care unit (ICU). 
The NLR is a potent indicator of  inflammation5, while the MPV is an indicator of platelet activation. In critically 
ill patients, inflammation causes vascular endothelial dysfunction in microcirculation as well as platelet activation 
and consumption. The NLR and MPV have been shown to be associated with poor prognosis in various cohorts, 
including those of patients with coronary artery disease, acute respiratory distress syndrome, cancer, and sepsis; 
those of elderly patients; and those of critically ill  patients6–10.
Although the association between NLR and mortality in critically ill patients has previously been investigated, 
few studies have considered the prognostic values of both NLR and MPV.
This study aimed to investigate whether the NLR and MPV/platelet ratio could be used to predict 1-year 
mortality in critically ill patients.
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Results
A total of 1344 patients were screened, and 1154 patients were included in the final analysis (Fig. 1). Table 1 shows 
the baseline characteristics and clinical data of patients stratified according to 6-month mortality. Non-survivors 
were significantly older than survivors (68.49 ± 14.63 vs. 62.22 ± 15.88 years, p < 0.001) and the ICU readmission 
rate was significantly higher among the non-survivors than among the survivors (10.4% vs. 4.2%, p < 0.001). The 
survivor group contained a significantly higher proportion of postoperative patients than the non-survivor group 
(68.1% vs. 44.8%, p < 0.001). Severity of illness scores were significantly higher in the non-survivor group than in 




 Paediatric patients (n=39)
Patients assessed for eligibility
(n = 1156)
Patients excluded (n=2)
 Lost to follow-up (n=2)
Patients screened
(n =1,344)
Figure 1.  Flowchart of study enrolment.
Table 1.  Baseline characteristics and outcome variables stratified according to 1-year mortality. Values are 
presented as the mean ± standard deviation or number of patients (%). ICU, intensive care unit; APACHE 
II, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; SAPS III, 
Simplified Acute Physiology Score; Hb, haemoglobin; WBC, white blood cell; NLR, neutrophil to lymphocyte 
ratio; PLT, platelet; MPV, mean platelet volume; HOD, hospital day.
Survivor (n = 866) Non-survivor (n = 288) p-value
Sex (M/F) 517/349 179/109 0.461
Age (years) 62.22 ± 15.88 68.49 ± 14.63  < 0.001
Cancer (n) 109 (28.4%) 131 (34.0%) 0.104
Postoperative patients (n) 590 (68.1%) 129 (44.8%)  < 0.001
Emergency operation (n) 147/590 (24.9%) 33/129 (25.6%) 0.874
ICU readmission (n) 36 (4.2%) 30 (10.4%)  < 0.001
APACHE II score 14.91 ± 7.04 19.98 ± 9.03  < 0.001
SOFA score 3.89 ± 3.16 5.92 ± 3.80  < 0.001
SAPS III 27.21 ± 17.12 36.93 ± 21.43  < 0.001
Hb (g/dL) 11.67 ± 6.00 10.46 ± 5.33 0.002
WBC  (103/µL) 11,676.43 ± 5932.20 12,621.27 ± 6873.87 0.038
Neutrophil  (103/µL) 9352.46 ± 5549.32 10,327.14 ± 5951.60 0.015
Lymphocyte  (103/µL) 1445.35 ± 1858.15 1214.46 ± 1112.58 0.011
NLR 10.18 ± 10.68 16.26 ± 25.42  < 0.001
PLT  (103/µL) 196.00 ± 89.81 200.82 ± 146.45 0.598
MPV 10.16 ± 0.97 10.46 ± 1.13  < 0.001
MPV/platelet 7.20 ± 11.78 8.97 ± 9.55 0.011
Hospital stay (day) 25.04 ± 58.00 28.10 ± 27.85 0.388
ICU stay (day) 4.67 ± 18.38 8.55 ± 13.28  < 0.001
Ventilator day (day) 1.96 ± 18.11 6.02 ± 14.82  < 0.001
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non-survivor group (p < 0.001). The SOFA score was 3.89 ± 3.16 in the survivor group compared to 5.92 ± 3.80 
in the non-survivor group (p < 0.001), while the Simplified Acute Physiology Score (SAPS III) was 27.21 ± 17.12 
in the survivor group compared to 36.93 ± 21.43 in the non-survivor group (p < 0.001). The white blood cell 
(WBC) count was higher in the non-survivor group than in the survivor group (12,621.27 ± 6873.87  103/µL 
vs. 11,676.43 ± 5932.20  103/µL, p = 0.038). Conversely, haemoglobin (Hb) levels were significantly higher in the 
survivor group than in the non-survivor group (11.67 ± 6.00 g/dL vs. 10.46 ± 5.33 g/dL, p = 0.002). The neutro-
phil count was higher in the non-survivor group than in the survivor group (10,327.14 ± 5951.60  103/µL vs. 
9352.46 ± 5549.32  103/µL, p = 0.015); in contrast, lymphocyte counts were higher in the survivor group than in 
the non-survivor group (1445.35 ± 1858.15  103/µL vs. 1214.46 ± 1112.58  103/µL, p = 0.011). The non-survivor 
group had a higher NLR than the survivor group (16.26 ± 25.42 vs. 10.18 ± 10.68, p < 0.001). The platelet count 
was not significantly different between the survivors (196.00 ± 89.81  103/µL) and non-survivors (200.82 ± 146.45 
 103/µL). The MPV and MPV/platelet ratio were both significantly higher in the non-survivor group than in the 
survivor group (MPV: 10.46 ± 1.13 vs. 10.16 ± 0.97, p < 0.001; MPV/platelet ratio: 8.97 ± 9.55 vs. 7.20 ± 11.78, 
p = 0.011). The length of ICU stay and duration of ventilator care were also longer in the non-survivor group 
than in the survivor group (ICU stay: 8.55 ± 13.28 days vs. 4.67 ± 18.38 days, p < 0.001; duration on ventilator: 
6.02 ± 14.82 days vs. 1.96 ± 18.11 days, p < 0.001).
Table 2 presents the categorisation of patients by baseline NLR tertiles, and Table 3 presents the categorisa-
tion of patients by the baseline MPV/platelet ratio. The highest severity of illness scores were observed in the 
third tertile (APACHE II score: 15.09 ± 7.47 vs. 15.68 ± 7.71 vs. 17.75 ± 8.25, p < 0.001; SOFA score: 3.97 ± 3.62 
vs. 4.14 ± 3.13 vs. 5.08 ± 3.47, p < 0.001; SAPS III: 27.82 ± 17.47 vs. 28.36 ± 18.10 vs. 32.71 ± 20.25, p < 0.001). 
The length of ICU stay and duration of ventilator care were significantly longer in the third tertile (ICU stay: 
4.48 ± 6.71 vs. 4.90 ± 7.81 vs. 7.53 ± 28.10, p = 0.030; ventilator duration: 1.83 ± 5.80 vs. 2.02 ± 6.50 vs. 5.06 ± 28.81, 
p = 0.015, respectively). The incidence of 6-month mortality was the highest in the third tertile for NLR (17.2% 
vs. 17.7% vs. 27.3%, p = 0.001). The incidences of in-hospital mortality and 1-year mortality were also the highest 
in the third tertile for NLR (in-hospital mortality: 11.2% vs. 11.9% vs. 21.0%, p < 0.001; 1-year mortality: 20.3% 
vs. 21.3% vs. 33.2%, p < 0.001).
The APACHE II score, SOFA score, and SAPS III were the highest in the third tertile for MPV/platelet ratio 
(APACHE II score: 15.67 ± 7.49 vs. 14.88 ± 7.35 vs. 17.96 ± 8.48, p < 0.001; SOFA score: 3.78 ± 3.18 vs. 3.55 ± 2.88 
vs. 5.85 ± 3.74, p < 0.001; SAPS III score: 27.98 ± 18.39 vs. 27.17 ± 17.91 vs. 33.74 ± 9.31, p < 0.001). The incidence 
rates of in-hospital, 6-month, and 1-year mortality were also the highest in the third tertile for MPV/platelet 
Table 2.  Baseline characteristics and outcome variables across NLR tertiles. Values are presented as the 
mean ± standard deviation or number of patients (%). ICU, intensive care unit; APACHE II, Acute Physiology 
and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; SAPS III, Simplified Acute 
Physiology Score; Hb, haemoglobin; WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; PLT, 
platelet; MPV, mean platelet volume; HOD, hospital day.
1st tertile (n = 384) 2nd tertile (n = 385) 3rd tertile (n = 385) p-value
Sex (M/F) 239/145 231/154 226/159 0.598
Age (years) 63.55 ± 16.00 63.31 ± 15.36 64.49 ± 16.07 0.549
Cancer (n) 109 (28.4%) 131 (34.0%) 135 (35.1%) 0.104
Postoperative patients (n) 238 (62.0%) 261 (67.8%) 220 (57.1%) 0.009
Emergency operation (n) 52 (21.8%) 62 (23.8%) 66 (30.0%) 0.111
ICU readmission (n) 21 (5.5%) 24 (6.2%) 21 (5.5%) 0.868
APACHE II score 15.09 ± 7.47 15.68 ± 7.71 17.75 ± 8.25  < 0.001
SOFA score 3.97 ± 3.62 4.14 ± 3.13 5.08 ± 3.47  < 0.001
SAPS III 27.82 ± 17.47 28.36 ± 18.10 32.71 ± 20.25  < 0.001
Hb (g/dL) 11.45 ± 5.45 11.80 ± 8.28 10.87 ± 2.14 0.084
WBC  (103/µL) 8841.46 ± 5067.20 11,822.81 ± 4770.51 15,070.82 ± 6877.90  < 0.001
Neutrophil  (103/µL) 5570.44 ± 3420.67 9720.99 ± 3957.66 13,485.24 ± 6136.57  < 0.001
Lymphocyte  (103/µL) 2178.07 ± 2679.12 1274.45 ± 561.96 712.71 ± 404.47  < 0.001
NLR 2.91 ± 1.33 7.87 ± 1.68 24.28 ± 22.48  < 0.001
PLT  (103/µL) 196.12 ± 96.40 204.32 ± 109.73 191.17 ± 113.20 0.225
MPV 10.17 ± 0.98 10.19 ± 1.00 10.34 ± 1.07 0.038
MPV/platelet ratio 7.73 ± 9.25 6.59 ± 4.33 8.62 ± 16.62 0.043
Hospital stay (day) 23.36 ± 34.52 25.28 ± 24.67 28.78 ± 79.73 0.344
ICU stay (day) 4.48 ± 6.71 4.90 ± 7.81 7.53 ± 28.10 0.030
Ventilator use (day) 1.83 ± 5.80 2.02 ± 6.50 5.06 ± 28.81 0.015
Mortality (n) 84 (21.9%) 93 (24.2%) 141 (36.6%)  < 0.001
In-hospital mortality (n) 43 (11.2%) 46 (11.9%) 81 (21.0%)  < 0.001
6-month mortality (n) 66 (17.2%) 68 (17.7%) 105 (27.3%) 0.001
1-year mortality (n) 78 (20.3%) 82 (21.3%) 128 (33.2%)  < 0.001
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ratio (in-hospital mortality: 13.5% vs. 8.6% vs. 22.3%, p < 0.001; 6-month mortality: 19.5% vs. 13.2% vs. 29.4%, 
p < 0.001; 1-year mortality: 25.5% vs. 16.4% vs. 33.0%, p < 0.001).
Based on the Kaplan–Meier curves for 1-year mortality, the log-rank test demonstrated that the MPV/plate-
let ratio was an independent risk factor for mortality in critically ill patients (p = 0.015). However, there were 
no significant differences in mortality between the tertiles of baseline NLR values based on the Kaplan–Meier 
curves (p = 0.498) (Fig. 2).
Discussion
This retrospective study investigated the association between the NLR and MPV/platelet ratio and 1-year mor-
tality in critically ill patients. We found that both the NLR and MPV/platelet ratio were significantly higher in 
the non-survivor group than in the survivor group. The 1-year mortality rate was significantly higher in patients 
in the third tertiles of both the NLR and MPV/platelet ratio than in patients in the lower tertiles. Moreover, the 
MPV/platelet ratio was independently associated with an increased risk of mortality at 1 year.
These findings are consistent with those of previous studies that identified the NLR as an independent predic-
tor of mortality. NLR was demonstrated to be an independent predictor of mortality in patients with cardiovas-
cular diseases such as acute coronary  syndrome6, pulmonary  embolism11,12, and aortic  dissection13,14. It also has 
been shown to predict outcomes in cancer  patients8.
The NLR increases in patients with neutrophilia and lymphopenia and is an indicator of systemic inflamma-
tion. NLR may reflect immune responses to surgical stress, systemic inflammation, or  sepsis5. A previous study 
reported that neutrophilia and lymphopenia were observed in critically ill oncological patients following major 
surgery, sepsis, and septic shock and that there was a correlation between the severity of the clinical course and 
the grades of neutrophilia and  lymphopenia5. This alteration in NLR is likely due to a stress-induced increase in 
serum cortisol levels. Furthermore, higher neutrophil counts induced by inflammation may contribute to the 
thrombotic state, explaining the utility of NLR as a predictor of poor  prognosis12.
The role of NLR as a prognostic indicator in sepsis patients is controversial. A previous study on critically 
ill patients with sepsis found that there was no significant relationship between NLR and mortality. However, 
NLR was associated with mortality in unselected critically ill patients, including sepsis  patients15. Additional 
studies have reported that NLR was associated with mortality in patients with  sepsis16–20. Hwang et al. demon-
strated that septic shock patients at risk of early death had a low NLR and that late death was associated with an 
increased  NLR21. These disparate results in sepsis patients are presumably due to the presence of variables such 
Table 3.  Baseline characteristics and outcome variables across MPV/platelet ratio tertiles. Values are presented 
as the mean ± standard deviation or number of patients (%). ICU, intensive care unit; APACHE II, Acute 
Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; SAPS III, Simplified 
Acute Physiology Score; Hb, haemoglobin; WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; PLT, 
platelet; MPV, mean platelet volume.
1st tertile (n = 384) 2nd tertile (n = 385) 3rd tertile (n = 385) p-value
Sex (M/F) 219/165 239/146 238/147 0.273
Age (years) 62.28 ± 17.19 63.83 ± 15.49 65.24 ± 14.54 0.036
Cancer (n) 134 (34.9%) 117 (30.4%) 124 (32.2%) 0.406
Postoperative patients (n) 233 (60.7%) 260 (67.5%) 226 (58.7%) 0.030
Emergency operation (n) 49 (21.0%) 65 (25.0%) 66 (29.2%) 0.130
ICU readmission (n) 26 (6.8%) 16 (4.2%) 24 (6.2%) 0.256
APACHE II score 15.67 ± 7.49 14.88 ± 7.35 17.96 ± 8.48  < 0.001
SOFA score 3.78 ± 3.18 3.55 ± 2.88 5.85 ± 3.74  < 0.001
SAPS III 27.98 ± 18.39 27.17 ± 17.91 33.74 ± 9.31  < 0.001
Hb (g/dL) 11.48 ± 5.25 12.21 ± 8.36 10.43 ± 2.08  < 0.001
WBC  (103/µL) 13619.48 ± 6161.08 11,533.59 ± 5590.39 10,585.24 ± 6411.66  < 0.001
Neutrophil  (103/µL) 10,963.35 ± 5957.43 9337.61 ± 5234.55 8489.71 ± 5514.95  < 0.001
Lymphocyte  (103/µL) 1576.40 ± 1080.22 1415.14 ± 971.15 1172.12 ± 2557.89 0.004
NLR 10.83 ± 11.16 10.24 ± 10.60 14.01 ± 22.71 0.013
PLT  (103/µL) 306.83 ± 104.67 184.03 ± 25.68 101.03 ± 34.05  < 0.001
MPV 9.67 ± 0.72 10.15 ± 0.85 10.23 ± 1.02  < 0.001
MPV/platelet 3.37 ± 0.76 5.59 ± 0.69 13.96 ± 17.86  < 0.001
Hospital stay (day) 26.85 ± 35.38 20.31 ± 18.33 30.26 ± 80.75 0.001
ICU stay (day) 5.57 ± 9.24 4.11 ± 5.00 7.24 ± 28.03 0.004
Ventilator use (day) 2.81 ± 8.95 1.77 ± 5.47 4.33 ± 28.27 0.046
Mortality (n) 106 (27.6%) 74 (19.2%) 138 (35.8%)  < 0.001
In-hospital mortality (n) 51 (13.3%) 33 (8.6%) 86 (22.3%)  < 0.001
6-month mortality (n) 75 (19.5%) 51 (13.2%) 113 (29.4%)  < 0.001
1-year mortality (n) 98 (25.5%) 63 (16.4%) 127 (33.0%)  < 0.001
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as neutropenia, depending on the severity of sepsis. Consistent with this, an inverse pattern was observed in the 
NLR of patients at risk of early death compared to those at risk of late  death21. Similarly, Hwang et al. reported 
comparable mortality rates in both the low and high NLR  groups16. These finding are supported by previous 
studies demonstrating that neutropenia is a predictive factor for mortality in septic shock  patients22. Therefore, 
our finding that NLR was associated with mortality in unselected critically ill patients, including sepsis patients, 
is consistent with previous  results15. However, the use of NLR as a predictive factor in critically ill patients should 
be interpreted with caution given the possible involvement of neutropenia and neutrophilia in the case of sepsis, 
particularly since sepsis patients account for a high proportion of ICU patients.
Elevated MPV was described as an indicator of mortality in previous reports, consistent with our results. 
Previous studies were primarily concerned with the increase in MPV over time or after disease progression, 
rather than the initial value. MPV was significantly higher in the non-survivor groups than in the survivor groups 
after the third day of admission in a previous meta-analysis on noncardiac critically ill  patients23. An increase 
Figure 2.  Kaplan–Meier survival curves for 1-year mortality according to the tertiles of neutrophil to 
lymphocyte ratio (NLR) (p = 0.498 based on the log-rank test) (a) and mean platelet volume (MPV)/platelet 
ratio (p = 0.015 based on the log-rank test) (b).
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in MPV during the first 72 h was an independent predictor for 28-day mortality in severe sepsis and/or septic 
shock  patients10. The MPV/platelet ratio at admission and on day 1 was a prognostic marker for 28-day mortality 
in patients with severe sepsis, consistent with the findings of this  study9.
MPV reflects the platelet size; therefore, an increase in MPV indicates an increase in platelet production 
and activation. Since platelet activation may contribute to the pathogenesis of the thrombotic complications of 
hypertension, platelet activation markers have been shown to increase with increasing severity of hypertensive 
 disease24. Further, MPV was significantly higher in patients with coronary artery calcification than in patients 
without. As such, MPV has been revealed as an independent predictor of coronary artery  calcification25,26. Eleva-
tion of MPV was also shown to be positively associated with arterial  stiffness27.
MPV has been shown to be an indicator of inflammation in various  diseases28,29. MPV was elevated in patients 
with malignant tumours compared to that in healthy subjects and decreased following  treatment30. Elevated MPV 
was also associated with various cardiovascular diseases related to atherosclerosis, a disease that is characterised 
by endothelial dysfunction and vascular  inflammation27,31,32. In critically ill patients, various conditions related 
to platelet activation that can lead to cardiovascular complications and inflammatory processes are important 
factors in determining prognosis. In this aspect, MPV can serve as a prognostic predictor for adverse outcomes 
in critically ill  patients33.
Previous studies have shown that both MPV and MPV/platelet ratio have predictive values. The inverse 
relationship between the total platelet count and MPV has previously been  described10,34–36. This inverse rela-
tionship was also observed in our study. When the patients were divided into 3 tertiles according to MPV, the 
platelet count decreased as the MPV value increased (data not shown: 1st tertile, 238.00 ± 103.57; 2nd tertile, 
190.75 ± 99.12; 3rd tertile, 159.10 ± 102.39; p < 0.001). Azab et al. demonstrated that the MPV/platelet ratio was 
superior to MPV alone in predicting mortality in patients with non ST-elevation myocardial  infarctions37. There-
fore, our study examined the MPV/platelet ratio and revealed the value of the MPV/platelet ratio as a predictor 
of mortality in critically ill patients.
In this study, both the NLR and MPV/platelet ratio were significantly higher among survivors. Moreover, the 
incidence of 1-year mortality was significantly higher in patients in the third tertiles of NLR and MPV/platelet 
ratio than in those in the lower tertiles. However, based on the Kaplan–Meier survival curve, NLR was not an 
independent risk factor for mortality while MPV/platelet ratio did represent a significant risk factor for mortality 
in critically ill patients. These findings could indicate that both the NLR and MPV/platelet ratio are meaningful 
as predictors of mortality in ICU patients but that the MPV/platelet ratio is more valuable than NLR. This dis-
crepancy could be due to the fact that NLR can be affected by changes in the neutrophil count and that MPV can 
reflect platelet activation. Given that both NLR and MPV reflect inflammation, it can function as a prognostic 
indicator. Further study will be needed to evaluate the differences between the NLR and MPV/platelet ratio as 
prognostic factors for mortality in critically ill patients.
The strength of this study was that we investigated the role of both NLR and MPV/platelet ratio as a prognostic 
predictor in critically ill patients, something that has not previously been given a great deal of consideration. 
Moreover, as revealed through the Kaplan–Meier survival analysis, we found that the MPV/platelet ratio, rather 
than NLR, was associated with patient survival in critically ill patients. The fact that previous studies mostly 
focused on the increase in MPV over time or after disease progression, rather than on the initial value, is another 
strength of this study. To our knowledge, few studies have investigated the predictive value of the initial MPV/
platelet value. As revealed in this study, the ability to predict prognosis through a complete blood count, an easy, 
convenient, and readily available laboratory test, will help personalise treatments and improve the prognosis 
for each patient.
This study has several limitations. The first is the retrospective nature of the study. Furthermore, although 
we demonstrated the value of the NLR and MPV/platelet ratio as a predictor of mortality, we could not identify 
correlations with other inflammatory markers. Additional prospective studies investigating correlations with 
other inflammatory markers will be needed to obtain more conclusive results. Finally, although the study was 
conducted in ICU patients, the patient group was heterogeneous. We included all patients admitted to the ICU 
during the study period. Thus, the study included a variety of patients such as surgical patients, patients with 
sepsis, cancer patients, and pneumonia patients. Although it is meaningful to reveal the prognostic value of the 
NLR and MPV/platelet ratio in these various critically ill patients, further studies will be needed to elucidate the 
meaning of each in a more homogenous patient group.
In conclusion, this retrospective study revealed that the MPV/platelet ratio was independently associated 
with an increased risk of 1-year mortality in critically ill patients. Further, we determined that NLR and MPV/
platelet ratio, an inexpensive and readily available marker at ICU admission, was a predictive factor for 1-year 
mortality in critically ill patients.
Methods
This study was approved by the institutional review board of Yonsei University Health System, Seoul, Korea 
(IRB protocol No. 3–2018-0264). The requirement for informed consent was waived by the IRB. All methods 
and procedures were carried out in accordance with the relevent guidelines and regulations. The study was per-
formed according to the tenests of the Declaration of Helsinki. We retrospectively reviewed patients admitted 
to the ICU between January 2017 and December 2017 (n = 1344). Patients who were re-admitted to the ICU in 
the same admission period (n = 91), paediatric patients (n = 39), and patients with insufficient data (n = 58) were 
excluded (Fig. 1). To assess the risk of mortality after ICU admission, patients were divided into 2 groups based 
on 1-year mortality (survivor: n = 866; non-survivor: n = 288). We compared the NLR and MPV/platelet ratio 
for each day of ICU admission. Patients were classified into tertiles according to the NLR (first tertile: NLR < 5.3 
[n = 384]; second tertile: NLR ≥ 5.3 ≤ 11.3 [n = 385]; and third tertile: NLR > 11.3 [n = 385]) and MPV/platelet 
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ratio (first tertile: MPV/platelet < 4.51 [n = 384]; second tertile: MPV/platelet ≥ 4.51 ≤ 7.07 [n = 385]; and third 
tertile: MPV/platelet > 7.07 [n = 385]).
We collected data on baseline patient characteristics including sex, age, history of readmission to the ICU, 
history of cancer, history of operation, severity of illness scores (including the APACHE II score, SOFA score, 
and SAPS III), laboratory data (including WBC count, Hb level, MPV, platelet count, neutrophil count, and 
lymphocyte count), and clinical outcomes (including hospital day, ICU day, and duration of ventilator use).
The NLR and MPV/platelet ratio measured on ICU admission were recorded. The baseline characteristics 
and clinical data, including those of NLR and MPV, were compared by dividing the patients into survivors and 
non-survivors according to 1-year mortality. Patients were categorised by tertiles of the baseline NLR and MPV/
platelet ratio. The primary outcome was the incidence of 1-year mortality in patients admitted to the ICU. The 
secondary outcomes were in-hospital mortality and 6-month mortality.
Blood samples for laboratory counts were collected into tubes containing ethylenediaminetetraacetic acid 
(EDTA). To prevent EDTA-induced platelet swelling, platelet counts and MPV were analysed with ADVIA 2120 
haematology analyser (Siemens, Forchheim, Germany) within 30 min of sample collection.
Statistical analysis. All statistical analyses were performed using SPSS version 23 (IBM Corp, Armonk, 
NY). Normality was assessed using the Kolmogorov–Smirnov test. The independent t-test or Mann–Whitney 
test was used to compare continuous variables. To compare three groups, the one-way analysis of variance or 
Kruskal–Wallis test was used, as appropriate. Categorical variables were compared using the chi-squared or 
Fisher’s exact test. Demographic and clinical data are presented as mean ± standard deviation or frequency (%). 
Kaplan–Meier survival curves were created to assess the probability of survival across the baseline NLR and 
MPV/platelet ratio tertiles according to 1-year mortality. The tertiles were compared by the log-rank test. A 
p-value < 0.05 was considered statistically significant.
Data availability
Materials, data and associated protocols are available.
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